Anavex Life Sciences (AVXL) Price & Analysis

Compare

1,670 Followers

AVXL Stock Chart & Stats

Day’s Range― - ―

52-Week Range$4.93 - $14.44

Previous CloseN/A

Volume1.46M

Average Volume (3M)1.09M

Market Cap

$807.40M

Enterprise Value$686.05M

Total Cash (Recent Filing)$101.16M

Total Debt (Recent Filing)$0.00

Price to Earnings (P/E)―

Beta1.59

Next Earnings

Dec 22, 2025

EPS Estimate

-0.14

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.16

Shares Outstanding85,893,840

10 Day Avg. Volume973,216

30 Day Avg. Volume1,089,826

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.85

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/Ebitda-9.63

Forecast

1Y Price Target

$42.00

Price Target Upside340.71% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

Bulls Say, Bears Say

Bulls Say

Drug DevelopmentPreclinical data with blarcamesine indicate ability to prevent Alzheimer's-like pathology, suggesting that this compound is an attractive candidate for Alzheimer's disease pharmacological prevention.

Regulatory AffairsPositive commentary from the European Medicines Agency could have a huge upside to the stock and indicate success with other ex-US regulatory bodies.

Bears Say

Partnership And ExpansionThe uncertainty around approval in the U.S. and lack of any ex-US partnership news are the key holdups for the stock.

Regulatory ChallengesThe FDA will likely require the company to run a larger Phase 3 study prior to an NDA submission.

Anavex Life Sciences News

Anavex reports new publication on mechanism with blarcamesine

Anavex (AVXL) Life Sciences reported a peer-reviewed publication in the journal iScience, ascertaining the precise autophagy mechanism of...

2d ago

AVXL

Anavex announces new publication on blarcamesine in Alzheimer’s

Anavex (AVXL) Life Sciences reported a peer-reviewed publication in the journal Neuroscience Letters, titled “Prevention of memory impairment...

8d ago

AVXL

Anavex reports Q3 EPS (16c) vs (14c) last year

“Our development of non-invasive, targeted upstream compounds continues to advance, particularly in the context of Alzheimer’s disease,” said...

16d ago

AVXL

Anavex announces precision medicine results of oral blarcamesine treatment

Anavex (AVXL) Life Sciences announced the latest findings for blarcamesine, an oral small molecule for the potential treatment...

28d ago

AVXL

Anavex Life Sciences: Navigating Legal Risks and Regulatory Challenges in a High-Stakes Industry

Anavex Life Sciences (AVXL) has disclosed a new risk, in the Litigation & Legal Liabilities category. Anavex Life...

14d ago

AVXL

Anavex Life Sciences Reports Q3 2025 Financial Results

Anavex Life Sciences ( ($AVXL) ) has released its Q3 earnings. Here is a breakdown of the information...

15d ago

AVXL

AVXL Earnings Report this Week: Is It a Buy, Ahead of Earnings?

Anavex Life Sciences (AVXL) is scheduled to report 3rd quarter earnings on 08/12/2025, before the market opens. Regarding...

18d ago

AVXL

Largest borrow rate increases among liquid names

Latest data shows the largest indicative borrow rate increases among liquid option names include: Prospect Capital (PSEC) 3.93%...

1M ago

AISP

AVXL

Closing Bell Movers: Trade Desk jumps 14% on S&P500 inclusion

In the opening hour of the evening session, U.S. equity futures are down about 0.1%, with S&P 500...

1M ago

APP

Anavex files $300M common stock offering

16:32 EDT Anavex (AVXL) files $300M common stock offering Published first on TheFly – the ultimate source for...

1M ago

AVXL

Anavex Life Sciences Amends Executive Employment Contracts

An update from Anavex Life Sciences ( ($AVXL) ) is now available. On July 3, 2025, Anavex Life...

2M ago

AVXL

Largest borrow rate increases among liquid names

Latest data shows the largest indicative borrow rate increases among liquid option names include: Sharplink Gaming Inc (SBET)...

2M ago

CGC

JCI

Anavex Life Sciences Approves Key Amendments at Annual Meeting

Anavex Life Sciences ( ($AVXL) ) has shared an update. On June 10, 2025, Anavex Life Sciences held...

3M ago

AVXL

Largest borrow rate increases among liquid names

Latest data shows the largest indicative borrow rate increases among liquid option names include: Anavex (AVXL) 11.73% +2.52,...

3M ago

NNE

RKT

AVXL FAQ

What was Anavex Life Sciences’s price range in the past 12 months?

Anavex Life Sciences lowest stock price was $4.93 and its highest was $14.44 in the past 12 months.

What is Anavex Life Sciences’s market cap?

Anavex Life Sciences’s market cap is $807.40M.

When is Anavex Life Sciences’s upcoming earnings report date?

Anavex Life Sciences’s upcoming earnings report date is Dec 22, 2025 which is in 116 days.

How were Anavex Life Sciences’s earnings last quarter?

Anavex Life Sciences released its earnings results on Aug 12, 2025. The company reported -$0.16 earnings per share for the quarter, missing the consensus estimate of -$0.142 by -$0.018.

Is Anavex Life Sciences overvalued?

According to Wall Street analysts Anavex Life Sciences’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Anavex Life Sciences pay dividends?

Anavex Life Sciences does not currently pay dividends.

What is Anavex Life Sciences’s EPS estimate?

Anavex Life Sciences’s EPS estimate is -0.14.

How many shares outstanding does Anavex Life Sciences have?

Anavex Life Sciences has 85,893,840 shares outstanding.

What happened to Anavex Life Sciences’s price movement after its last earnings report?

Anavex Life Sciences reported an EPS of -$0.16 in its last earnings report, missing expectations of -$0.142. Following the earnings report the stock price went down -5.022%.

Which hedge fund is a major shareholder of Anavex Life Sciences?

Currently, no hedge funds are holding shares in AVXL

Anavex Life Sciences Stock Smart Score

Neutral

Fundamentals

Return on Equity

-43.63%

Trailing 12-Months

Asset Growth

-27.67%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Anavex Life Sciences

Anavex Life Sciences Corp. is a clinical-stage biopharmaceutical company dedicated to the development of novel drug candidates to treat central nervous system (CNS) diseases. The company is primarily focused on developing therapies for Alzheimer's disease, Parkinson's disease, and other neurodegenerative and neurodevelopmental disorders. Anavex's lead compound, ANAVEX2-73 (blarcamesine), is being studied for its potential to modify disease progression and improve symptoms in these conditions.

Anavex Life Sciences (AVXL) Earnings & Revenues

Historic Earnings Reports

AVXL Earnings Call

Q3 2025

0:00 / 0:00

Earnings Call Sentiment|Neutral

The earnings call presents a balanced view with strong ongoing development and financial health, but also challenges in administrative costs and net losses. The company's advancements in Alzheimer's treatment and cash flow are positive, but operational costs and delays in Parkinson's study present concerns.View all AVXL earnings summaries

AVXL Stock 12 Month Forecast

Average Price Target

$42.00

▲(340.71% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"3":"$3","13":"$13","23":"$23","33":"$33","43":"$43"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":42,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$42.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":42,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$42.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":42,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$42.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[3,13,23,33,43],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2024","6":"Jan<br/>2025","9":"Apr<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,11.2,13.569230769230769,15.938461538461539,18.307692307692307,20.676923076923075,23.046153846153846,25.415384615384614,27.784615384615385,30.153846153846153,32.52307692307692,34.892307692307696,37.261538461538464,39.63076923076923,{"y":42,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,11.2,13.569230769230769,15.938461538461539,18.307692307692307,20.676923076923075,23.046153846153846,25.415384615384614,27.784615384615385,30.153846153846153,32.52307692307692,34.892307692307696,37.261538461538464,39.63076923076923,{"y":42,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,11.2,13.569230769230769,15.938461538461539,18.307692307692307,20.676923076923075,23.046153846153846,25.415384615384614,27.784615384615385,30.153846153846153,32.52307692307692,34.892307692307696,37.261538461538464,39.63076923076923,{"y":42,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":4.06,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.11,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.58,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.44,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.84,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.32,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.74,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.27,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.91,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.02,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.31,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.56,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.2,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >